IL2 and type 1 diabetes mellitus: In fact, there is an ongoing clinical study in children with recent-onset T1D assessing IL-2 at the lowest doses with its repeated administration over a longer period than those tested to date, aimed at defining the lowest sufficient dose of IL-2 and establishing kinetics of Treg enhancement, allowing suitable adjustment of its administration schedule [26].